Twist Bioscience Corp banner

Twist Bioscience Corp
NASDAQ:TWST

Watchlist Manager
Twist Bioscience Corp Logo
Twist Bioscience Corp
NASDAQ:TWST
Watchlist
Price: 56.7 USD -4.14% Market Closed
Market Cap: $3.5B

P/E

-45.4
Current
287%
More Expensive
vs 3-y average of -11.7

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-45.4
=
Market Cap
$3B
/
Net Income
$-76.6m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-45.4
=
Market Cap
$3B
/
Net Income
$-76.6m

Valuation Scenarios

Twist Bioscience Corp is trading above its industry average

If P/E returns to its Industry Average (19.1), the stock would be worth $-23.91 (142% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-150%
Maximum Upside
No Upside Scenarios
Average Downside
146%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple -45.4 $56.7
0%
Industry Average 19.1 $-23.91
-142%
Country Average 22.9 $-28.58
-150%

Forward P/E
Today’s price vs future net income

Not enough data available to calculate forward P/E

Peer Comparison

All Countries
Close
Earnings Growth PEG
US
Twist Bioscience Corp
NASDAQ:TWST
Average P/E: 34.1
Negative Multiple: -45.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
86.1
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
23.6
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
16%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
19%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
14%
1.2
NL
argenx SE
XBRU:ARGX
36.7
30%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
29.8
9%
3.3

Market Distribution

Lower than 100% of companies in the United States of America
Percentile
0th
Based on 8 489 companies
0th percentile
-45.4
Low
0 — 15.3
Typical Range
15.3 — 33.2
High
33.2 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 15.3
Median 22.9
70th Percentile 33.2
Max 1 826 183.3

Twist Bioscience Corp
Glance View

In the bustling world of biotechnology, Twist Bioscience Corp. has emerged as a trailblazer with its innovative approach to DNA synthesis technology. Founded on the premise of leveraging the power of synthetic DNA, Twist has unraveled the potential of precision engineering in genetics. The company operates with a unique silicon-based DNA synthesis platform, which allows for the rapid and cost-effective production of high-quality DNA. This cutting-edge technology facilitates advancements in various domains such as drug development, agricultural biology, and data storage. By addressing the ever-growing demand for synthesized DNA across these sectors, Twist positions itself at the intersection of technology and life sciences, offering a robust solution that fuels the DNA-driven innovations of tomorrow. At its core, Twist Bioscience generates revenue by providing its customers with a streamlined supply of custom DNA products, catering to researchers and businesses that require precise genetic sequences with high fidelity. This includes synthetic genes, oligonucleotide pools, and libraries used for CRISPR screening and other applications. The company has strategically diversified its offerings to include specialized DNA libraries and biopharmaceutical solutions, further extending its reach into therapeutic discovery and development. By aligning its business model with the needs of its clients, Twist ensures consistent growth by capitalizing on the expanding markets of biotechnology and synthetic biology, turning its pioneering technological capabilities into a profitable enterprise.

TWST Intrinsic Value
38.83 USD
Overvaluation 32%
Intrinsic Value
Price $56.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett